Our current analysis cannot exclude the possibility that the patient criteria for considering GLP-1 M treatment are generalizable for other T2D medications since we only considered GLP-1 M and did not compare it with responsiveness to other treatments. This evidence concerns the gene GCG and type 2 diabetes mellitus.